Cart
sales@molnova.com
SB-216
CAS No. 2756818-39-8
SB-216( —— )
Catalog No. M35469 CAS No. 2756818-39-8
SB-216 is able to be used for the research of cancer which is a potent inhibitor of tubulin polymerization.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 74 | Get Quote |
|
| 5MG | 112 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 321 | Get Quote |
|
| 50MG | 459 | Get Quote |
|
| 100MG | 621 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSB-216
-
NoteResearch use only, not for human use.
-
Brief DescriptionSB-216 is able to be used for the research of cancer which is a potent inhibitor of tubulin polymerization.
-
DescriptionSB-216 is a potent tubulin polymerization inhibitor. SB-216 shows strong antiproliferative potency in a panel of human cancer cell lines, including melanoma, lung cancer, and breast cancer.? SB-216 can be used for cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMicrotubule Associated
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2756818-39-8
-
Formula Weight310.35
-
Molecular FormulaC17H18N4O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (201.39 mM; Ultrasonic )
-
SMILESCOc1ccc2N(CC(=O)Nc2c1)c1nc(C)nc2CCCc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Souvik Banerjee, et al. X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. J Med Chem. 2021 Sep 9;64(17):13072-13095.?
molnova catalog
related products
-
(S)-VU0637120
(S)-VU0637120 is a selective neuropeptide Y(4)R-mutant antagonist used in the study of metabolic disorders.
-
A-H-A
A-H-A
-
Glofitamab
Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell killing by binding to CD20 on malignant cells.
